EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

METTL5 stabilizes c‐Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression

Peng Xia, Hao Zhang, Haofeng Lu, Kequan Xu, Xiang Jiang, Yuke Jiang, Xiangdong Gongye, Zhang Chen, Jie Liu, Xi Chen, Weijie Ma, Zhonglin Zhang und 1 weitere

Cancer Communications · 2023

DOI: 10.1002/cac2.12403 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, 2023. Verfasst von Peng Xia und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary & Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, P. R. China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 174-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Research Fund of the Health Commission of Hubei Province, National Basic Research Program of China, Natural Science Foundation of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocellular carcinoma (HCC) is one of the most prevalent cancers in the world, with a high likelihood of metastasis and a dismal prognosis. The reprogramming of glucose metabolism is critical in the development of HCC. The Warburg effect has recently been confirmed to occur in a variety of cancers, including HCC. However, little is known about the molecular biological mechanisms underlying the Warburg effect in HCC cells. In this study, we sought to better understand how methyltransferase 5, N6‐adenosine (METTL5) controls the development of HCC and the Warburg effect.

Methods

In the current study, quantitative real‐time polymerase chain reaction and Western blotting were used to detect the expression of METTL5 in HCC tissues and cell lines. Several different cell models and animal models were established to determine the role of METTL5 in glucose metabolism reprogramming and the underlying molecular mechanism of HCC. Glutathione‐S‐transferase pulldown, coimmunoprecipitation, RNA sequencing, non‐targeted metabolomics, polysome profiling, and luciferase reporter assays were performed to investigate the molecular mechanisms of METTL5 in HCC cells.

Results

We discovered that METTL5 drove glucose metabolic reprogramming to promote the proliferation and metastasis of HCC. Mechanistically, upregulation of METTL5 promoted c‐Myc stability and thus activated its downstream glycolytic genes lactate dehydrogenase A ( LDHA ), enolase 1 ( ENO1 ), triosephosphate isomerase 1 ( TPI1 ), solute carrier family 2 member 1 ( SLC2A1 ), and pyruvate kinase M2 ( PKM2 ). The c‐Box and ubiquitin binding domain (UBA) regions of ubiquitin specific peptidase 5 (USP5) binded to c‐Myc protein and inhibited K48‐linked polyubiquitination of c‐Myc. Further study revealed that METTL5 controled the USP5 translation process, which in turn regulated the ubiquitination of c‐Myc. Furthermore, we identified cAMP responsive element binding protein 1 (CREB1)/P300 as a critical transcriptional regulator of METTL5 that promoted the transcription of METTL5 in HCC. In patient‐derived tumor xenograft (PDX) models, adenovirus‐mediated knockout of METTL5 had a good antitumor effect and prolonged the survival of PDX‐bearing mice.

Conclusions

These findings point to a novel mechanism by which CREB1/P300‐METTL5‐USP5‐c‐Myc controls abnormal glucose metabolism and promotes tumor growth, suggesting that METTL5 is a potential therapeutic target and prognostic biomarker for HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAnimalsHumansMiceCell Line, TumorGlucosePrognosisUbiquitin-Specific ProteasesMethyltransferases

Stichwörter der Autor:innen

CREB1METTL5P300USP5c-Mycdeubiquitinationglucose metabolismhepatocellular carcinoma

Substanzen

GlucoseUbiquitin-Specific ProteasesUsp5 protein, mouseMETTL5 protein, humanMethyltransferases

Autor:innen und Institutionen

  • Department of Hepatobiliary & Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, P. R. China.
  • Clinical Medicine Research Center for Minimally Invasive Procedure of Hepatobiliary & Pancreatic Diseases of Hubei Province, Wuhan, Hubei, P. R. China.
  • Department of Hepatobiliary Surgery, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, P. R. China.
  • Department of Clinical and Translational Research Center, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology),…

ORCID-Profile: Yufeng Yuan

Förderung

  • Research Fund of the Health Commission of Hubei Province
  • National Basic Research Program of China
  • Natural Science Foundation of Hubei Province

Zitieren

APA

Xia, P., Zhang, H., Lu, H., Xu, K., Jiang, X., Jiang, Y., Gongye, X., Chen, Z., Liu, J., Chen, X., Ma, W., Zhang, Z., & Yuan, Y. (2023). METTL5 stabilizes c‐Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression. Cancer Communications. https://doi.org/10.1002/cac2.12403

Vancouver

Xia P, Zhang H, Lu H, Xu K, Jiang X, Jiang Y, et al. METTL5 stabilizes c‐Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression. Cancer Communications. 2023. doi:10.1002/cac2.12403

BibTeX
@article{Xia2023,
  author = {Xia, Peng and Zhang, Hao and Lu, Haofeng and Xu, Kequan and Jiang, Xiang and Jiang, Yuke and Gongye, Xiangdong and Chen, Zhang and Liu, Jie and Chen, Xi and Ma, Weijie and Zhang, Zhonglin and Yuan, Yufeng},
  title = {METTL5 stabilizes c‐Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression},
  journal = {Cancer Communications},
  year = {2023},
  doi = {10.1002/cac2.12403}
}
Kostenlos starten →